Impact of UGT1A1 Gilbert Variant on Discontinuation of Ritonavir-Boosted Atazanavir in AIDS Clinical Trials Group Study A5202
| Autor: | Eric S. Daar, Katie R. Mollan, David W. Haas, Gene D. Morse, Paul E. Sax, Camlin Tierney, Margaret A. Fischl, Ann C. Collier, Heather J. Ribaudo |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
medicine.medical_specialty
Efavirenz Genotype Anti-HIV Agents Pyridines Atazanavir Sulfate Jaundice HIV Infections Pharmacology Emtricitabine Major Articles and Brief Reports chemistry.chemical_compound Abacavir Antiretroviral Therapy Highly Active Internal medicine medicine Humans Immunology and Allergy Glucuronosyltransferase Ritonavir business.industry Genetic Variation virus diseases Lamivudine Bilirubin Discontinuation Atazanavir Infectious Diseases chemistry HIV-1 business Oligopeptides medicine.drug |
| Zdroj: | The Journal of Infectious Diseases. 207:420-425 |
| ISSN: | 1537-6613 0022-1899 |
| Popis: | The UGT1A1*28 variant has been associated with hyperbilirubinemia and atazanavir discontinuation. Protocol A5202 randomly assigned human immunodeficiency virus type 1 (HIV-1)-infected patients to receive atazanavir/ritonavir (atazanavir/r) or efavirenz, with tenofovir/emtricitabine or abacavir/lamivudine. A total of 646 atazanavir/r recipients were evaluable for UGT1A1. Homozygosity for *28/*28 was present in 8% of whites, 24% of blacks, and 18% of Hispanics and was associated with increased bilirubin concentrations. There was an association between *28/*28 and increased atazanavir/r discontinuation among Hispanic participants (P = .005) but not among white or black participants (P = .79 and P = .46, respectively). The positive predictive value of 28*/28* for atazanavir/r discontinuation among Hispanic participants was only 32% (95% confidence interval, 16%-52%). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|